3 questions hanging over the Novo-Catalent deal

As backlash builds for the recently announced matchup, critical questions remain over its impact.

By Kelly Bilodeau • Feb. 13, 2024

Could Novo, Lilly become first trillion-dollar healthcare companies?

Explosive demand for weight loss drugs has propelled both companies to new heights. Here’s a look at the staggering growth, by the numbers.

By Meagan Parrish • Feb. 2, 2024

10 of our most read articles in 2023

A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

By Meagan Parrish • Dec. 22, 2023

What are pharma’s next blockbusters?

In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.

By Kelly Bilodeau • Dec. 20, 2023

Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next

Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.

By Michael Gibney • Dec. 12, 2023

Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV

Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

By Alexandra Pecci • Dec. 11, 2023

What if a CRISPR cure isn’t such an easy choice?

A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

By Ned Pagliarulo , Shaun Lucas • Nov. 9, 2023

What’s next for COVID dark horse Novavax?

Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?

By Kelly Bilodeau • Oct. 30, 2023

Red Jacket: Adele Gulfo, a commercialization guru

With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

By Karissa Waddick • Oct. 27, 2023

3 marketing tips for biotechs emerging from stealth

In a crowded biotech market, here’s how your company can stand out to investors.

By Karissa Waddick • Oct. 6, 2023

PharmaVoice 100s: Brand and commercialization pros

Leaders decoding the complex language of drug development to push treatments past the finish line and into patients’ hands.

By Karissa Waddick • Oct. 4, 2023

How pharma marketers can reclaim the drug pricing narrative

As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.

By Karissa Waddick • Sept. 28, 2023

Optimizing your hub services program with a gross-to-net lens

In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.

Sept. 25, 2023

As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.

By Michael Gibney • Sept. 21, 2023

Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

By Michael Gibney • Sept. 15, 2023

O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad

The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups. 

By Karissa Waddick • Sept. 14, 2023

In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.

By Michael Gibney • Sept. 14, 2023

Finding the right flu vaccine is hard. Getting people to take it is harder.

Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.

By Michael Gibney • Aug. 30, 2023

Are weight loss drugs a win for the global economy?

As Novo Nordisk’s drug Wegovy sways Denmark’s economy, we're examining wider implications for the weight loss market. 

By Karissa Waddick • Aug. 28, 2023

Henrietta Lacks’ immortal cells put biopharma profits under a microscope

The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

By Michael Gibney • Aug. 23, 2023

Behind Flagship Pioneering’s triumphs and tribulations

From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.

By Karissa Waddick • Aug. 18, 2023

Demand for weight loss drugs soars to nearly half of Americans

Drugs like the buzzy Ozempic are high on consumers’ radar — but lofty barriers to access remain.

By Alexandra Pecci • Aug. 15, 2023

Woman of the Week: Novartis’ Christy Siegel

The oncology portfolio general manager for breast and women’s cancers, discusses the company’s recent “landmark” trial and how her family’s history connects her to patients.

By Taren Grom and Meagan Parrish • Aug. 15, 2023

PBMs could soon feel the regulatory sting

From Congress to the FTC to state legislatures, regulators are cracking the whip against PBMs.

By Karissa Waddick • Aug. 4, 2023

Putting purpose over profits, this pharma takes on the important issues

Afaxys is a self-described "socially conscious" contraceptive healthcare company serving an unusual demographic for pharma: the public health sector.

By Alexandra Pecci • Aug. 1, 2023